Oramed Pharmaceuticals (NASDAQ:ORMP) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Oramed Pharmaceuticals (NASDAQ:ORMP) released its earnings results on Thursday. The biotechnology company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02, Zacks reports.

Oramed Pharmaceuticals Stock Down 1.0%

NASDAQ:ORMP traded down $0.03 on Friday, hitting $3.29. The stock had a trading volume of 38,932 shares, compared to its average volume of 208,699. Oramed Pharmaceuticals has a 52 week low of $1.82 and a 52 week high of $3.76. The business’s fifty day moving average is $3.41 and its 200 day moving average is $2.91. The company has a market cap of $130.87 million, a PE ratio of 2.61 and a beta of 1.31.

Oramed Pharmaceuticals Dividend Announcement

The company also recently declared a dividend, which was paid on Monday, January 26th. Shareholders of record on Friday, January 16th were issued a $0.25 dividend. The ex-dividend date was Friday, January 16th. Oramed Pharmaceuticals’s dividend payout ratio is presently 19.84%.

Institutional Trading of Oramed Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Bank of America Corp DE increased its stake in Oramed Pharmaceuticals by 4.4% during the 3rd quarter. Bank of America Corp DE now owns 149,667 shares of the biotechnology company’s stock valued at $395,000 after purchasing an additional 6,261 shares in the last quarter. XTX Topco Ltd lifted its stake in shares of Oramed Pharmaceuticals by 59.9% in the fourth quarter. XTX Topco Ltd now owns 38,182 shares of the biotechnology company’s stock valued at $109,000 after buying an additional 14,297 shares in the last quarter. Jane Street Group LLC lifted its stake in shares of Oramed Pharmaceuticals by 35.3% in the first quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company’s stock valued at $144,000 after buying an additional 17,510 shares in the last quarter. Squarepoint Ops LLC grew its holdings in shares of Oramed Pharmaceuticals by 95.1% during the fourth quarter. Squarepoint Ops LLC now owns 58,272 shares of the biotechnology company’s stock valued at $166,000 after buying an additional 28,406 shares during the last quarter. Finally, Quadrature Capital Ltd bought a new stake in shares of Oramed Pharmaceuticals during the fourth quarter worth about $119,000. Institutional investors and hedge funds own 12.73% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “hold (c)” rating on shares of Oramed Pharmaceuticals in a research note on Monday, December 29th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock currently has an average rating of “Hold”.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.